Thermadyne Holdings reports Q3 net sales up 19.0% to $106.5mln.

• Thermadyne Holdings reported Q3 2010 net sales of $106.5mln, up 19% YoY. • Net income from continuing ops increased to $4.8mln, up from $3.7mln in Q3 2009. • Earnings per diluted share from continuing ops rose to $0.35, up from $0.27 in Q3 2009. • Digital data not specifically mentioned in the article.

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) has reiterated its full-year 2025 financial guidance while raising its adjusted EBITDA forecast. The company announced that it expects LINZESS U.S. net sales to range between $800 million and $850 million, with total Ironwood revenue projected to be between $260 million and $290 million [1]. Additionally, Ironwood has raised its adjusted EBITDA guidance to greater than $105 million for 2025.

In the first quarter of 2025, Ironwood reported continued strong prescription demand growth of 8% year-over-year for LINZESS, the company's U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) [1]. However, the company noted that this growth was offset by anticipated pricing headwinds and a change in the estimate of AbbVie gross-to-net rebate reserves, which was refined to reflect rebates owed for units dispensed in the first quarter of 2025.

Ironwood's chief executive officer, Tom McCourt, stated, "We are reiterating our full-year 2025 LINZESS U.S. net sales and total Ironwood revenue guidance. In the first quarter of 2025, we saw continued strong prescription demand growth of 8% year-over-year, which was offset by anticipated pricing headwinds as well as a change in estimate of AbbVie gross-to-net rebate reserves, which was refined to reflect rebates owed for units dispensed in the first quarter of 2025. We do not expect first quarter LINZESS U.S. net sales results or this change in estimate to impact the full-year results."

The company also noted that the change in estimate of gross-to-net rebate reserves will continue to be based on rebates owed for units dispensed by channel in each applicable quarter, and that this change in estimate is expected to have a neutral impact on the full-year results.

Ironwood's 2025 financial guidance is as follows:
- U.S. LINZESS Net Sales: $800 - $850 million
- Total Revenue: $260 - $290 million
- Adjusted EBITDA: Greater than $105 million

Ironwood Pharmaceuticals is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases. The company is advancing apraglutide, a next-generation, long-acting synthetic GLP-2 analog, and has been a pioneer in the development of LINZESS® (linaclotide), the U.S. branded prescription market leader for adults with IBS-C or CIC.

References:
[1] https://www.businesswire.com/news/home/20250425289111/en/Ironwood-Pharmaceuticals-Reiterates-Full-Year-2025-LINZESS-U.S.-Net-Sales-Guidance-and-Raises-Adjusted-EBITDA-Guidance